Impax Generics












Metaxalone 400 mg TabletsImpax Generics

Our New Identity

Impax Generics, formerly Global Pharmaceuticals, is the multiple-source products division of Impax Laboratories, Inc. Earlier in 2015, Impax completed the acquisition of Tower Holdings, Inc. Subsequently, two operating subsidiaries of Tower – CorePharma LLC and Lineage Therapeutics Inc. – were combined with Global Pharmaceuticals to form the newly named Impax Generics division. We have increased our commercial portfolio of products, broadened our R&D efforts and strengthened our generic pipeline. In addition, we have expanded and diversified our manufacturing, packaging and supply chain capabilities.

Our Portfolio

Impax Generics continues to focus on the development, manufacture and commercialization of complex generic pharmaceutical products and our recent acquisition enhances this strategy. Our core competencies include expertise in controlled-release products, controlled substances and other difficult to formulate products. Using our controlled-release drug delivery technologies and formulation skills we develop bioequivalent versions of selected brand name pharmaceuticals, many of which have technically challenging drug delivery requirements. Our specialty generics portfolio also includes the epinephrine injection, USP auto-injector, an authorized generic of Adrenaclick® (epinephrine injection, USP) auto-injector.

We bring value to our customers with innovative products in key therapeutic areas. We currently market 48 generic pharmaceutical products. The newest products in our portfolio include ursodiol tablets (equivalent to Urso® [ursodiol]) in two strengths, 250 mg and 500 mg, and metaxalone tablets (equivalent to Skelaxin® [metaxalone]) in the 400 mg strength.¹

Epinephrine Injection, USP Auto-Injector





Our Pipeline

The generic pipeline consists of 31 products pending at FDA, 12 of which are either confirmed or potential first-to-file or first-to-market opportunities.² We also have a number of products in various stages of development. Our pipeline is well diversified with a mix of solid-oral and alternative dosage form products across a broad range of therapeutic areas.

Our Mission

Our mission is to ensure the availability of high-quality, affordable generic pharmaceuticals and bring value to our customers while conducting our business with uncompromising integrity and ethics.

1 Data as of May 1, 2015

2 Data as of March 10, 2015


Impax Generics

A division of:
Impax Laboratories, Inc.
30831 Huntwood Avenue
Hayward, California 94544

Key contact:
Vice President
Sales and Marketing
Phone: 215-558-4352

Related Videos
© 2024 MJH Life Sciences

All rights reserved.